Claims for Patent: 7,491,691

Summary for Patent: 7,491,691

Title:	Connective tissue stimulating peptides
Abstract:	Novel peptides are described which comprise an amino acid motif selected from the group consisting of \"PG\", \"GP\", \"PI\" and \"IG\" and having up to 10 amino acids upstream and/or downstream of the amino acid motif, wherein \"P\" in the motif is proline or hydroxyproline and the peptide stimulates the development, maintenance and repair of bone, cartilage and associated connective tissue. The invention further relates to pharmaceutical compositions of these peptides, as well as therapeutic and prophylactic uses of such peptides.
Inventor(s):	Sindrey; Dennis R. (Oakville, Ontario, CA), Pugh; Sydney M. (Glenburnie, Ontario, CA), Smith; Timothy J. N. (Kingston, Ontario, CA)
Assignee:
Application Number:	10/513,202
Patent Claims:	1. An isolated, bone and/or cartilage development-stimulating peptide selected from the group consisting of NGLPGPIGP* (SEQ ID NO. 1); NGLPGPIG (SEQ ID NO. 2); NGLP*GPIG (SEQ ID NO. 3); NGLP*GPIGP* (SEQ ID NO. 4); NGLPGP (SEQ ID NO. 5); PGPIG (SEQ ID NO. 7); NGLPGPIGP (SEQ ID NO. 8); PGPIGP (SEQ ID NO. 9); PGPIGPPGPR (SEQ ID NO. 10); GPIG (SEQ ID NO. 11); PGPIGPPGPRGRTGDA (SEQ ID NO. 12); GPRGRTGDA (SEQ ID NO. 13); PGPIGPP (SEQ ID NO. 14); PGPIGP* (SEQ ID NO. 15); PGPI (SEQ ID NO. 16); GLPGPIG (SEQ ID NO. 17); GPIGP* (SEQ ID NO. 18); and PIGP (SEQ ID NO. 20), wherein P is proline or hydroxyproline, and further wherein P* is hydroxyproline. 2. The peptide of claim 1, which is NGLPGPIGP* (SEQ ID NO. 1). 3. The peptide of claim 1, which is PGPIG (SEQ ID NO. 7). 4. The peptide of claim 1, wherein P is proline. 5. The peptide of claim 1, which is NGLPGPIG (SEQ ID NO. 2). 6. The peptide of claim 1, which is NGLP*GPIG (SEQ ID NO. 3). 7. The peptide of claim 1, which is NGLP*GPIGP* (SEQ ID NO. 4). 8. The peptide of claim 1, which is NGLPGP (SEQ ID NO. 5). 9. The peptide of claim 1, which is NGLPGPIGP (SEQ ID NO. 8). 10. The peptide of claim 1, which is PGPIGP (SEQ ID NO. 9). 11. The peptide of claim 1, which is PGPIGPPGPR (SEQ ID NO. 10). 12. The peptide of claim 1, which is GPIG (SEQ ID NO. 11). 13. The peptide of claim 1, which is PGPIGPPGPRGRTGDA (SEQ ID NO. 12). 14. The peptide of claim 1, which is GPRGRTGDA (SEQ ID NO. 13). 15. The peptide of claim 1, which is PGPIGPP (SEQ ID NO. 14). 16. The peptide of claim 1, which is PGPIGP* (SEQ ID NO. 15). 17. The peptide of claim 1, which is PGPI (SEQ ID NO. 16). 18. The peptide of claim 1, which is GLPGPIG (SEQ ID NO. 17). 19. The peptide of claim 1, which is GPIGP* (SEQ ID NO. 18). 20. The peptide of claim 1, which is PIGP (SEQ ID NO. 20). 21. The peptide of claim 1, wherein said peptide stimulates the activity of bone cells, bone cell precursors and cells sharing lineage therewith. 22. The peptide of claim 1, wherein said peptide stimulates the activity of cartilage cells, cartilage cell precursors and cells sharing lineage therewith. 23. The peptide of claim 1, wherein said peptide stimulates the formation of bone. 24. The peptide of claim 1, wherein said peptide stimulates the formation of cartilage. 25. The peptide of claim 1, wherein said peptide stimulates a response in vitro, ex vivo and/or in vitro. 26. The peptide of claim 1, wherein P is hydroxyproline. 27. A pharmaceutical composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier. 28. The pharmaceutical composition of claim 27, wherein said composition further comprises an agent selected from the group consisting of calcium phosphate, calcium sulfate, calcium carbonate, fibrin, hyaluronic acid, proteoglycans, calcitonin, estrogen, estradiol, prostaglandin A1, bisphosphonic acids, ipriflavones, sodium fluoride, vitamin K, bone morphogenetic proteins, fibroblast growth factor, platelet-derived growth factor, transforming growth factor, insulin-like growth factors 1 and 2, endothelin, parathyroid hormone, epidermal growth factor, leukemia inhibitory factor, osteogenin and mixtures thereof. 29. The pharmaceutical composition of claim 27, wherein said composition may be administered locally and/or systemically. 30. The pharmaceutical composition of claim 29, wherein systemic administration is selected from intravenous injection, intramuscular injection, intraperitoneal injection, oral administration, enteral administration, parenteral administration, intranasal administration, pulmonary administration, topical administration, transdermal administration and combinations thereof. 31. The peptide of claim 29, wherein local administration is provided by injection or use with an implant. 32. The peptide of claim 31, wherein said peptide is provided as a coating, filling or dispersed within a matrix of said implant. 33. The peptide of claim 32, wherein said peptide is provided with a granular or powdered biomaterial compound.

Details for Patent 7,491,691

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2022-05-03